Evidence map›Paper›PMID 40766306›Full record

Trial reportFrontiers in immunology2025

Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3.

Xin Tong, Ross Blanc, Deniz Cizmeci, Hadar Malca, Jaewon Kang, Christy Comeaux, Benoit Callendret, Arangassery Rosemary Bastian, Mehak Zahoor Khan, Galit Alter and 2 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xin TongRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Ross BlancRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Deniz CizmeciRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Hadar MalcaDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, United States.
Jaewon KangRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Christy ComeauxJanssen Vaccines & Prevention B.V., Leiden, Netherlands.
Benoit CallendretJanssen Vaccines & Prevention B.V., Leiden, Netherlands.
Arangassery Rosemary BastianJanssen Vaccines & Prevention B.V., Leiden, Netherlands.
Mehak Zahoor KhanRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Galit AlterRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Daniel LingwoodRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.
Ryan P McNamaraRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, United States.

Funding

SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
NIAID NIH HHS R01 AI146785NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447
6 · The paper itself

Abstract

Introduction: Respiratory syncytial virus (RSV) causes significant lower-respiratory-tract disease in high-risk groups. A phase IIb trial showed that a combination vaccine of Ad26-vectored prefusion RSV F (Ad26.preF) plus soluble prefusion F protein (SpreF) was 80 % protective, yet the longevity and functionality of these humoral responses are unknown. Methods: Sera from vaccinated adults were analyzed 12 months after the primary dose and 28 days after a homologous booster at 1 year. IgG subclasses, isotypes, Fc-γ receptor (FcγR) binding, and Fc-dependent effector functions including opsinophagocytosis against RSV-F subtypes A and B were quantified via Systems Serology. Results: A single dose generated durable immunity: IgG3-driven opsonophagocytic activity and broad FcγR engagement (via IgG1, IgG2, and IgG3) persisted through 12 months without appreciable decay. The booster did not increase antibody titres, FcγR binding, or functional activity, indicating that the primary response had already plateaued. Discussion: One dose of Ad26.preF + SpreF elicits a long-lasting, functionally potent humoral response that is not further enhanced by a booster at 12 months, suggesting limited benefit from early re-vaccination. Continued follow-up will clarify the duration of protection and inform booster timing in vulnerable populations.

Indexed as

Antibodies, ViralGlycoproteinsImmunoglobulin GPhagocytosisRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesViral Fusion ProteinsAdultFemaleGenetic VectorsHumansImmunity, HumoralImmunization, SecondaryMaleMiddle AgedAntibodies, ViralGlycoproteinsImmunoglobulin GReceptors, IgGRespiratory Syncytial Virus VaccinesVaccines, CombinedViral Fusion Proteinsadenovirus vectorantibodyprefusion glycoproteinRSVvaccine

Identifiers

PMID40766306
PMCPMC12322566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.